艾立布林联合吡咯替尼加曲妥珠单克隆抗体新辅助治疗人表皮生长因子受体-2阳性局部晚期乳腺癌一例

Eribulin combined with pyrotinib and trastuzumab for neoadjuvant therapy in human epidermal growth factor receptor-2 positive locally advanced breast cancer:one case report

紫杉类药物化疗联合曲妥珠单克隆抗体加帕妥珠单克隆抗体的双靶治疗是HER-2阳性乳腺癌患者新辅助治疗的标准方案[1]。笔者报道1例多西紫杉醇化疗联合双靶治疗失败的HER-2阳性局部晚期乳腺癌,改用艾立布林联合吡咯替尼加曲妥珠单克隆抗体治疗,取得了良好的治疗效果。